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Accepted 29 March 2010AbstractObjective: There is a need to develop alternative therapeutic strategies to overcome cisplatin-associated resistance in patients with ovarian
cancer. Histone deacetylation (HDAC) associated with inactivation of genes has been implicated in the epigenetic silencing of tumor suppressor
genes affecting critical biological activities in cancer cells and may be an important factor in acquired cisplatin-associated resistance. In this
report, we tested a combination of cisplatin and LBH589 (histone deacetylation inhibitor) in cisplatin-resistant ovarian cancer cells to explore the
reversal effect of cisplatin resistance and changes of gene expression.
Materials and Methods: To detect the synergistic effects of antiproliferation between cisplatin and LBH589 in ovarian cancer cells, we per-
formed a cell viability assay and a clonogenic assay. To investigate the differences of gene expression between cells treated by cisplatin alone
and cotreated with cisplatin and LBH589, a microarray mRNA analysis was performed.
Results: In the presence of low-dose LBH589, the inhibition concentration value of cisplatin for A2780-cp70 cells was much lower than with
cisplatin treatment alone. Gene expression profiles identified that a total of 354 genes had been significantly upregulated and a total of 63 genes
been downregulated with LBH589 cotreatment.
Conclusion: We hypothesized that combination of cisplatin and LBH589 can override cisplatin-associated resistance in ovarian cancer cells.
These results provide initial evidence for testing this combination in clinical use.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Cisplatin or carboplatin-based regimens have been intro-
duced into clinical practice as the first-line chemotherapy for
ovarian cancer after debulking surgery [1]. Intrinsic or* Corresponding author. Department of Public Health, Chung-Shan Medical
University, No. 110, Section 1, Jianguo North Road, Taichung City 402,
Taiwan.
E-mail address: dinoljc@csmu.edu.tw (C.-C. Lung).
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doi:10.1016/j.tjog.2011.01.022acquired drug resistance, however, remains a major obstacle
resulting in a poor prognosis in patients receiving therapy [2].
Therefore, there is a need to develop alternative therapeutic
strategies to overcome cisplatin-associated resistance for
ovarian cancer patients. In the last two decades, reversal of
cisplatin resistance in cancer cells had raised great interest for
some clinicians and scientists. Several chemicals and drugs
have been evaluated as cisplatin sensitizers, including 12-
O-tetradecanoylphorbol-13-acetate [3,4], 2-propylpentanoic
acid (valproic acid) [5], 20-deoxy-5-azacytidine (AZAC) [6],cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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and cyclooxygenase inhibitors [10]. However, at present, there
is no widely accepted standard application clinically effective
for delaying tumor progression in platinum-resistant disease.
Because cisplatin-induced toxicity is dose limiting, to discover
a method to reduce the working dosage of cisplatin will be
a great contribution to patients with advanced disease.
Drug resistance of cancer cells resulting from gene tran-
scription, through complex mechanisms of genetic and
epigenetic modifications, is a significant cause of chemo-
therapy failure in patients with advanced cancers [11,12].
DNA methylation and histone deacetylation (HDAC) are two
major mechanisms of epigenetic modification, which play an
important role in regulating gene expression [13]. In many
forms of cancer, abnormal transcriptional activation and
inactivation of genes frequently occurs, and HDAC has been
implicated in epigenetic silencing of tumor suppressor genes
affecting critical biological activities in cancer cells [14].
Moreover, aberrant HDAC expression in tumors was found to
be associated with poor response to chemotherapy, but the
mechanisms leading to drug resistance are not fully known
[15]. Treatment with inhibitors of HDAC (HDACi) has shown
to have suppressive effects against various tumor cells by
inhibiting cell proliferation and inducing cell cycle arrest and
apoptosis. Previous studies have also shown that HDACi can
alter gene expression of cancer cells with respect to DNA
damage response, mitosis, angiogenesis, and signal trans-
duction [16,17]. Therefore, HDACi have been used clinically
as promising anticancer drugs. LBH589 (Panobinostat),
a potent hydroxamic acid-derived pan-HDAC inhibitor [18],
has been effectively used for treating cutaneous T-cell
lymphoma [19,20]. At present, there are more than 40 clinical
trials using LBH589 for the treatment of hematological and
solid malignancies (http://clinicaltrials.gov/).
For overcoming acquired drug resistance in cancers in vivo
or cancer cells in vitro, researchers have attempted to use
HDACi in combination with existing chemotherapeutic agents
[5,21e23]. One example is that treatment of cisplatin-resistant
ovarian cancer cells with decitabine and belinostat greatly
enhanced the effects on the cisplatin sensitivity of xenografts
and resulted in a marked increase in the expression of epige-
netically silenced MLH1 when compared with decitabine
alone [23]. It has also been reported that a combination of
cisplatin and valproic acid possesses HDACi activity, resen-
sitizes cisplatin response, and increases cytotoxicity via
phosphorylation of the ataxia telangiectasia mutation (ATM)
in cisplatin-resistant ovarian cancer cells [5]. In this study, we
treated cisplatin-resistant cell lines with a combination of
cisplatin and LBH589 to explore the reversal effect of cisplatin
resistance and changes of gene expression.
Materials and methodsCell linesThe parental A2780-12 cell line was maintained in Dul-
becco’s Modified Eagle Medium supplemented with 10% fetalbovine serum and 1% antibiotic mixture (penicillin, strepto-
mycin, and glutamine) in a humidified 5% CO2 incubator at
37C. The resistant cell line, A2780-cp70, was derived from
the A2780-12 cell line. These cell lines were kindly provided
by Dr Lin [5].Drugs and chemicalsCisplatin was obtained from Bristol Myers Squibb Co.
(Princeton, NJ, USA), and AZAC was bought from Sigma-
Aldrich Co. (St. Louis, MO) LBH589 was bought from
Novartis Co., Ltd. (Taipei, Taiwan) and provided by Dr. Chang
(Director, National Institute of Cancer Research, NHRI,
Taiwan).RNA extraction and purificationTotal RNA of A2780-cp70 cells treated with cisplatin and
LBH589 and A2780-cp70 cells treated with cisplatin alone
for 24 hours were extracted by Trizol (Invitrogen, Carlsbad,
CA, USA), and purified with a RNeasy Mini Kit (Qiagen,
Germany). RNA purification was quantified at OD260nm by
a ND-1000 spectrophotometer (Nanodrop Technology, USA)
and qualitated with a Bioanalyzer 2100 (Agilent Technology,
Palo Alto, CA, USA).Cell viability assayQuantification of cell viability was done using a water-
soluble tetrazolium salts-1 Kit (Biovision, CA, USA). Cells
were plated and harvested in 96-well plates at 3,000 cells per
well in a final volume of 200 mL/well of culture medium. At 24
hours after plating, cisplatin alone or in combination with
5 nM LBH589 or 8.8 mM AZAC was tested in various serial
dilutions in 200 mL of new media for each cell line. The cancer
cells were continuously incubated for 3 days with each drug
concentration in triplicate wells. Next, the medium in each
well, including empty wells which served as controls, was
replaced with 110 mL of culture medium containing 10 mL/
well water-soluble tetrazolium salts/electro-coupling solution
for 2 hours, then shaken thoroughly for 1 minute on a shaker.
The optical density (OD) of the wells was measured in an
ELISA Microplate Reader at 450 nm and 630 nm (reference
OD). The OD correlates linearly with the number of viable
cells.Clonogenic assayCells were cultured overnight in six-well plates in 3 mL
culture medium and then treated with cisplatin and LBH589
at various concentrations. After 14 days, the cells were fixed
and stained with 0.25% crystal violet and 10% ethanol for 5
minutes. The colony number (>50 cells/colony) were counted
and calculated as surviving fractions by dividing by the initial
number of cells in the plate. The percentage of colony number
was expressed related to control.
A2780-CP70A
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BMicroarray experiments were carried out following the
manufacturer’s protocols. Briefly, 0.5 mg of total RNA was
amplified by a Fluorescent Linear Amplification Kit (Agilent
Technologies, USA) and labeled with Cy3-CTP or Cy5-CTP
(CyDye; PerkinElmer, Norwalk, CT, USA). During the
in vitro transcription process, A2780-cp70 RNA treated with
cisplatin and LBH589 was labeled with Cy5 and RNA treated
with cisplatin alone was labeled by Cy3. Next, 0.825 mg of Cy-
labled cRNA was fragmented to an average size of 50e100
nucleotides by incubation with fragmentation buffer (Agilent
Technologies, USA) at 60C for 30 minutes. Fragmented
labeled cRNA was then pooled and hybridized to an Agilent
Whole Human Genome 4 44 k oligo microarray (Agilent
Technologies, USA) at 60C for 17 hours. After washing and
drying via a nitrogen gun, microarrays were scanned with an
Agilent microarray scanner (Agilent Technologies, USA) at
535 nm for Cy3 and 625 nm for Cy5. Scanned images were
analyzed with Feature extraction software 9.5.3 (Agilent
Technologies, USA), an image analysis and normalization
software used to quantify signal and background intensity for
each feature, substantially normalizing the data by the rank-
consistency-filtering LOWESS method.
Results0
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Cisplatin concentration ( M)Enhancement of cisplatin sensitivity in A2780-cp70 cells
by 5 nM LBH589Fig. 1. (A and B) Effects of LBH589 sensitize cisplatin-mediated cytotoxicity
on ovarian cell lines. A2780-cp70 cell (A) and A2780-12 (B) were plated
and harvested in 96-well plates at 3,000 cells per well; cisplatin alone or
combination with 5 nM LBH589 or 8.8 mM AZAC were tested in various
concentrations after 24 hours. Quantification of cell viability was done by
using WST-1 and performed in independently triplicate experiments.
AZAC¼ 2’-deoxy-5-azacytidine; bars¼ standard error; points¼ average of
three independent experiments.To detect the synergistic effects of growth inhibition and
antiproliferation between cisplatin and LBH589 in cancer
cells, we performed cell a viability assay and a clonogenic
assay. The parental and resistant cells were treated with
increasing concentrations of cisplatin in combination with
either fixed LBH589 (5 nM) or AZAC (8.8 mM) concentration
over a period of 72 hours. In cell viability assays, the
combined treatment had a greater inhibition effect in A2780-
cp70 cells than in A2780-12 cells, as shown in Fig. 1A.
LBH589 and AZAC both enhanced cisplatin sensitivity in
A2780-cp70 cells, and treatment with LBH589 and AZAC
together exhibited a superior effect in overcoming acquired
cisplatin resistance in A2780-cp70 cells. In A2780-cp70 cells
treated with cisplatin and LBH589, the inhibition concentra-
tion (IC50) value by cisplatin was approximately 15.7 mM; and
for cells treated with cisplatin alone, it was about 33.2 mM
(data not shown). The combination of LBH589 (5 nM) and
cisplatin in resistant cells resulted in enhancement of growth
inhibition, whereas the potentiation of growth inhibition was
absent in parental cells, that is, A2780-12 (Fig. 1B). Overall,
in the presence of low-dose LBH589, the IC50 of A2780-cp70
was lower than with cisplatin treatment alone.
Clonogenic assays showed that LBH589 can resensitize
A2780-cp70 cells to cisplatin. Low-nanomolar concentrations
of LBH589 and cisplatin were sufficient to kill cisplatin-
resistant cells, that is, A2780-cp70. The concentration of
cisplatin resulting in 50% cell death (EC50) was approximately1.37 mM in combination with 5 nM of LBH589, whereas the
EC50 for the cells treated with cisplatin alone was approxi-
mately 4.78 mM (Fig. 2). The reversal index of EC50 of
cotreatment with LBH589 and cisplatin was approximately
3.5-fold more potent than cisplatin treatment alone. Base on
these results, LBH589 can enhance the cytotoxicity effects
of cisplatin in A2780-cp70 cells. However, no significant
difference was not observed when LBH589 was added first,
concomitantly, or subsequently to the cisplatin-treated cells
(data not shown).Effects of LBH589 on gene expression in A2780-cp70
cells with cisplatin treatmentAs mentioned above, the combined results of cell the
viability and clonogenic assays revealed that low-dose
LBH589 increased the effectiveness of cisplatin to inhibit
the proliferation of A2780-cp70 cells in comparison with
cisplatin treatment alone. To investigate the differences of
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Fig. 2. Clonogenic assay of A2780-cp70 cells cotreated with LBH589 and
cisplatin. The concentration of cisplatin resulting in 50% cell death (EC50) was
about 1.37 mM in combination with 5 nM of LBH589, whereas the EC50 for
the cells treated with cisplatin alone was about 4.78 mM. Cells were cultured
overnight in six-wells plates in 3 mL culture medium and then treated with
cisplatin and LBH589 at various concentrations. After 14 days, the cells were
fixed and stained. The colony number (>50 cells/colony) were counted and
calculated as surviving fractions by dividing the initial number of cells in the
plate. The percentage of colony number was expressed related to control.
Points¼ average of three independent experiments; bars¼ standard error.
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cisplatin alone, a microarray mRNA analysis was performed.
As shown in Table 1, cotreatment with LBH589 and cisplatin
in A2780-cp70 cells, as compared with treatment with
cisplatin alone, was effective in increasing or decreasing the
expression levels of a variety of genes associated with ion/
channel/pore class transporter activity, hydrolase activity,
nucleotide binding/cellular physiological process, nucleotide
binding/telomerase activity, transferase activity, transcription
factor activity, immune response/receptor activity, immune
response/receptor binding, nucleic acid binding, and other
uncategorized functions. Overall, more genes were activated
than suppressed. Gene expression profiles of A2780-cp70 cells
altered by LBH589 treatment identified that a total of 354 genes
had been significantly upregulated (cDNA expression of 2-
fold) and a total of 63 genes had been significantly down-
regulated (cDNA expression of0.5-fold). The number of genes
showing a 2- or 0.5-fold change in expression was approx-
imately 417. Among them, 85%were upregulated, whereas only
15% were downregulated. The additional treatment of LBH589
in cells with cisplatin resulted in a striking induction of TEP1
andARNTL2 genes (up to 10-fold induction), as well as CASP8,
0 POLR3E, and AL13357 (up to 6-fold induction). On the other
hand, a significant suppressed gene (down to 0.22-fold reduc-
tion) was TRPC2, and similar effects were shown in LINCR and
TNRC6B (0.29- and 0.39-fold reduction).Discussion
Our results showed that LBH589 at a low concentration
(5 nM) increased the sensitivity of cisplatin-resistant ovarian
cancer cell lines to cisplatin. HDAC catalyzed by HDACi is
associated with transcriptional repression and increasingly
thought to play a role in the development of human cancers
[13,14]. This study aimed to investigate the influence of
a combination of cisplatin and LBH589 on antiproliferative
activity in cisplatin-resistant ovarian cancer cells. We also
performed a microarray RNA analysis to evaluate changes of
gene expression after concurrent treatment with LBH589 and
cisplatin. The combination treatment had a greater inhibition
effect in A2780-cp70 cells than A2780-12 cells as determined
by a cell viability assay. In addition, a clonogenic assay
showed remarkable reversal of cisplatin resistance by 5 nM of
LBH589 in A2780-cp70 cells. Gene expression profiles were
altered in A2780-cp70 cells after adding LBH589 to cisplatin
treatment, and more genes were activated than suppressed.
These genes may play roles in various cellular biological
pathways to increase cisplatin sensitivity in A2780-cp70 cells.
In clinical practice, cisplatin and HDACi are known as
antiproliferative agents and used in the treatment of a variety
of malignancies [2,16,17,19,24]. Cisplatin is a platinum-based
chemotherapeutic agent and induces DNA cross-links and
adducts, as well as the generation of superoxide radicals.
HDACi function as modifiers of histone and nonhistone
proteins via inhibiting deacetylation and then trigger the
reexpression of certain genes, which play important roles in
antitumor activity [16,17,19]. LBH589 is a potent pan-HDACi,
causing cell cycle arrest in G2/M and has been shown to kill
tumor cell lines both in vitro and in vivo [18,25e28]. Using
LBH589 to inhibit HDAC activity is a rational therapeutic
strategy currently in clinical development. Recent studies
have demonstrated synergistic antiproliferative effects in
cells cotreated with a chemotherapeutic drug and HDACi
[21e23,29,30]. In the present study, the phenotype of cisplatin-
associated resistance in A2780-cp70 cells was observed when
only cisplatin was added. The result was consistent with
previous study [5]. However, when cells were cotreated with
cisplatin and LBH589 at a concentration of 5 nM, greater
inhibitory effects were seen in A2780-cp70 cells than in
A2780-12 cells. Notably, the reversal factor of resistance was
3.5-fold. The results revealed that LBH589 may act as
a sensitizing drug and can be combined with cisplatin to
overcome the cisplatin resistance phenotype. Collectively, the
results indicate that LBH589 can sensitize A2780-cp70 cells to
cisplatin and lead to inhibition of the proliferation of tumor
cells. Furthermore, because LBH589 was effective at the
nanomolar level, it may have a safer toxicity profile than
traditional chemotherapeutic agents. These important results
may potentially expand more clinical applications of LBH589
and benefit patients with advanced or recurrent ovarian cancer
by increasing cisplatin sensitivity of tumors and reducing the
required cisplatin dosage to minimize its side effects.
To investigate the growth inhibition in cells treated with
LBH589 and cisplatin, an inhibitor of DNA methyltransferase,
Table 1
Candidate genes possibly involved in HDACi effect to increase cisplatin sensitivity of A2780-cp70 cells by microarray mRNA analysisa
Gene name Fold change Genbank Description
Upregulated
Ion/channel/pore class transporter activity
SLC1A1 2.15 NM_004170 Solute carrier family 1, member 1
SLC40A1 2.08 NM_014585 Solute carrier family 40, member 1
SLC17A5 2.08 NM_012434 Solute carrier family 17, member 5
GJE1 2.12 BC038207 Gap junction protein, epsilon 1
STEAP1 2.32 NM_012449 Six transmembrane epithelial antigen of the prostate 1
SCN2B 2.04 NM_004588 Sodium channel, voltage-gated, type II, beta
KCNMB4 2.31 NM_014505 Potassium large conductance calcium-activated channel, subfamily M, beta member 4
KCNA7 2.15 NM_031886 Potassium voltage-gated channel, shaker-related subfamily, member 7
Hydrolase activity
CASP8 6.97 NM_033355 Caspase 8, apoptosis-related cysteine peptidase
FRAS1 2.35 NM_025074 Fraser syndrome 1
PDE4C 2.04 Z46632 HSPDE4C1 gene for 30,50-cyclic AMP phosphodiesterase
DUSP23 2.17 NM_017823 Homo sapiens dual specificity phosphatase 23
GLB1L 2.15 NM_024506 Galactosidase, beta 1-like
KLK10 2.08 NM_002776 Kallikrein-related peptidase 10
KLK8 2.91 NM_144505 Kallikrein-related peptidase 8
SULF2 2.69 NM_018837 Homo sapiens sulfatase 2
AF086125 2.09 AF086125 Full-length insert cDNA clone ZA79D12
Nucleotide binding/cellular physiological process
GNL3L 4.80 NM_019067 Guanine nucleotide binding protein-like 3 (nucleolar)-like
MAT1A 2.47 NM_000429 Methionine adenosyltransferase I, alpha
KIF5C 2.78 NM_004522 Kinesin family member 5C
NLRP1 2.13 BC051787 NLR family, pyrin domain containing 1
VCX 4.31 NM_013452 Variable charge, X-linked
VCX3A 4.18 NM_016379 Variable charge, X-linked 3A
Nucleotide binding/telomerase activity
TEP1 12.63 NM_007110 Telomerase-associated protein 1
Transferase activity
GSTA1 4.09 NM_145740 Glutathione S-transferase A1
GSTA2 3.15 NM_000846 Glutathione S-transferase A2
GSTA5 3.09 NM_153699 Glutathione S-transferase A5
NMNAT2 3.31 NM_015039 Nicotinamide nucleotide adenylyltransferase 2
AS3MT 3.92 NM_020682 Arsenic (þ3 oxidation state) methyltransferase
PNMT 2.98 NM_002686 Phenylethanolamine N-methyltransferase
UST 2.05 NM_005715 Uronyl-2-sulfotransferase
POLR3E 6.83 AB040885 Homo sapiens mRNA for KIAA1452 protein, partial cds
AK125361 2.16 AK125361 Homo sapiens cDNA FLJ43371 fis, clone NTONG2005969
AL133570 6.23 AL133570 Homo sapiens mRNA; cDNA DKFZp434L201
Transcription factor activity
ARNTL2 10.72 AF256215 Cycle-like factor CLIF
BHLHB3 2.95 NM_030762 Basic helix-loop-helix domain containing, class B, 3
ONECUT2 2.38 NM_004852 One cut domain, family member 2
PBX2 2.03 NM-002586 Homo sapiens pre-B-cell leukemia transcription factor 2
ZIC1 2.05 NM-003412 Zic family member 1
SNFT 2.43 NM_018664 Jun dimerization protein p21SNFT
STON1 2.32 NM_006873 Stonin 1
Immune response/receptor activity
CXCR4 4.30 NM_001008540 Chemokine (C-X-C motif) receptor 4
HLA-DMA 2.65 NM_006120 Major histocompatibility complex, class II, DM alpha
HLA-DMB 2.38 NM_002118 Major histocompatibility complex, class II, DM beta
HLA-DPA1 2.00 NM_033554 Major histocompatibility complex, class II, DP alpha 1
HLA-DRB5 2.46 NM_002125 Major histocompatibility complex, class II, DR beta 5
PTPRF 2.04 NM_002840 Protein tyrosine phosphatase, receptor type, F
IFNAR2 3.45 NM_207585 Interferon alpha receptor 2
IL3RA 2.42 NM_002183 Interleukin 3 receptor, alpha
Immune response/receptor binding
TNFSF10 2.25 NM_003810 Tumor necrosis factor (ligand) superfamily, member 10
XCL1 2.05 NM_002995 Chemokine (C motif) ligand 1
XCL2 2.20 NM_003175 Chemokine (C motif) ligand 2
C3 2.36 NM_000064 Complement component 3
(continued on next page)
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Table 1 (continued)
Gene name Fold change Genbank Description
Downregulated
Ion binding/transporter activity
SLC25A25 0.48 NM_001006641 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25
SLC39A7 0.45 NM_006979 Solute carrier family 39 (zinc transporter), member 7
RASSF1 0.48 NM170713 Ras association (RalGDS/AF-6) domain family 1
TRPC2 0.22 NR_002720 Transient receptor potential cation channel, subfamily C, member 2
Transferase activity
ABL1 0.47 NM_005157 v-abl Abelson murine leukemia viral oncogene homolog 1
SNRK 0.43 NM_017719 SNF-related kinase
Nucleic acid binding
TNFAIP3 0.48 NM_006290 Tumor necrosis factor, alpha-induced protein 3
Chaperone activity
BAG5 0.48 NM_001015049 BCL2-associated athanogene 5
Uncategorized
HNRPCL1 0.43 NM_001013631 Heterogeneous nuclear ribonucleoprotein C-like 1
TNRC6B 0.39 NM_015088 Trinucleotide repeat containing 6B
LINCR 0.29 BC012317 Likely ortholog of mouse lung-inducible neutralized-related C3HC4 RING domain protein
a The genes showing a 2- or 0.5-fold changes in the ratios of cDNA expression is known as significant threshold.
BCL2¼B-cell lymphoma 2; HDACi¼ inhibitors of histone deacetylation; SNF¼ sucrose nonfermentor.
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LBH589 at a concentration of 5 nMwas as effective as AZAC at
a concentration of 8.8 mM in inhibiting cell growth, indicating
that LBH589 combined with cisplatin could be as clinically
useful as AZAC. Although combined treatment with LBH589
and AZAC revealed a synergistic effect to resensitize cisplatin
resistance in A2780-cp70 cells, the toxicity of AZAC remains
a clinical limitation to be considered. Moreover, the superior
effect of treatment with LBH589 and AZAC together implies
that the formation of acquired cisplatin resistance in ovarian
cancer may result from different epigenetic mechanisms.
Awhole-genome expression microarray was used to explore
the possible genes involved in acquired cisplatin resistance
mediated through HDAC in A2780-cp70 cells treated with
LBH589 (Table 1). Previous studies have observed upregula-
tion of cell cycle inhibitor p21 in response to LBH589 treat-
ment [22,25,27,28,31]. However, p21 has not been universally
observed to be upregulated [20,32,33]. The absence of p21
expression in A2780-cp70 may reflect a feature of the cell line.
Furthermore, several genes associated with cell cycle arrest and
apoptosis (e.g. ATM, CASP8, CYCS) were increased in our
study, suggesting that the predominant effects of LBH589 on
A2780-cp70 cells are cell cycle arrest and cell apoptosis. Since
the de-expression and re-expression of other genes were
observed, LBH589 may participate in controlling cell cycle
regulation through the effects of gene expression. On the other
hand, distinct expression changes in a variety of genes in
A2780-cp70 cells following treatment with cisplatin and/or
LBH589 were observed, and more genes were activated than
suppressed. A unique set of genes that may have roles in bio-
logical responses, such as apoptosis and antiproliferative
effects on cell growth, were observed in A2780-cp70 cells. A
previous study indicated that LBH589 may attenuate the
expression of Bcr-Abl protein and lead to suppression of
Bcr-Abl expression in human leukemia cells [34]. Based on
this study, it is plausible that the inhibition of cell proliferation
in A2780-cp70 by combined cisplatin and LBH589 may atleast partially be explained because of the attenuation of
Bcr-Ab1 by LBH589. Therefore, these genes may play a role in
mediating the resistant phenotype of cisplatin in A2780-cp70
cells, and further investigation is warranted.
On the basis of our findings, we hypothesize that the
combination of cisplatin and LBH589 can override cisplatin-
associated resistance in ovarian cancer cells. These results
provide initial evidence for testing this combination in clinical
use. Further in vivo research and clinical trials have to be
pursued to verify the preliminary results. Whether epigenetic
alterations of certain candidate genes are associated with the
reversal of cisplatin resistance remains to be investigated in
the future.
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